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CD23 is a 'low affinity', transmembrane receptor for IgE that is expressed on B cells and other leukocytes. 1 Transmembrane CD23 can be released from the cell-surface to form soluble CD23, which also binds IgE, and exerts cytokine-like activities on B cells and other leukocytes. 1 Soluble CD23 sustains growth of B cell precursors 2 , promotes B and T cell differentiation, 3, 4 and drives cytokine release from monocytes 5 .
The release of CD23 is mediated by membrane metalloproteases of the ADAM (a disintegrin and metalloprotease) family. ADAM10 is principally responsible for the constitutive and calcium-induced shedding of CD23.
6, 7
Damage-associated molecular patterns (DAMPs) are essential in inflammation and immunity, and function as signals for cell stress, tissue injury and disease.
Extracellular adenosine 5'-triphosphate (ATP) is a well-characterised DAMP that
activates the P2X7 receptor, a trimeric cation channel, which plays important roles in health and disease. 9 Activation of P2X7 by extracellular ATP causes the uptake of organic cations such as ethidium + and YO-PRO-1 2+ . 10 P2X7 activation induces a number of downstream effects including the shedding of CD23 from human malignant B cells 11, 12 and human dendritic cells 13, 14 . Recently our group demonstrated that P2X7-induced CD23 shedding from the human multiple myeloma cell line, RPMI 8226, is mediated by ADAM10. 15 2' (3')-O-(4-Benzoylbenzoyl) ATP (BzATP)-induced CD23 shedding from murine B cells is also mediated by ADAM10, 16, 17 but a direct role for P2X7 in this process was not established in these studies. Therefore, it remains unknown if P2X7 activation induces CD23 shedding from murine B cells, as well as from human B cells. The current study demonstrates that P2X7 activation induces the rapid shedding of CD23 from primary human and murine B cells and that this process possibly involves ADAM10.
Results

P2X7 activation induces rapid CD23 shedding from human B cells
ATP and BzATP at concentrations of 1 mM and 0.3 mM, respectively cause nearmaximal activation of human P2X7. 18 Therefore, to first determine if ATP induces To determine whether ATP-induced CD23 loss was mediated by P2X7, PBMCs were incubated for 6 min (the t 1/2 ) in the absence or presence of 1 mM ATP, the most potent P2X7 agonist 0.3 mM BzATP, or the non-P2X7 agonists 1 mM adenosine diphosphate (ADP) and uridine 5'-triphosphate (UTP). ATP and BzATP induced a 49 ± 9% and 60 ± 9% loss of cell-surface CD23, respectively, while ADP and UTP had no effect on CD23 expression compared to cells incubated without nucleotide ( Figure   1c ).
The P2X7 antagonist AZ10606120, 19 at a concentration of 100 nM results in nearcomplete inhibition of human P2X7. 20 Therefore, to confirm that ATP-induced loss of CD23 was mediated by P2X7, PBMCs were pre-incubated in the absence or presence of 100 nM AZ10606120, and 1 mM ATP-induced CD23 loss determined by flow cytometry. AZ10606120 impaired ATP-induced CD23 loss by 89 ± 12% (Figure 1d ).
In the absence of ATP, AZ10606120 did not alter CD23 expression (Figure 1d ).
To determine if the P2X7-induced loss of cell-surface CD23 was due to CD23
shedding, PBMCs were incubated in the absence or presence of 1 mM ATP for 20 min, and the relative amount of soluble CD23 in cell-free supernatants quantified by ELISA. Incubation of cells with ATP resulted in a significantly higher release of soluble CD23 compared with cells incubated in the absence of ATP (Figure 1e ).
Murine B cells express functional P2X7
The presence of functional P2X7 on primary human B cells is well-established, 21 but less well known for murine B cells. Similar to human P2X7, ATP and BzATP at concentrations of 1 mM and 0.3 mM, respectively result in near-maximal activation of murine P2X7. 18 While the P2X7 antagonist AZ10606120, at a concentration of 10 µM results in near-complete inhibition of murine P2X7. 22 Therefore, to first test whether functional P2X7 was present on murine B cells from C57BL/6 and DBA/1 mice, splenic cells from these two strains were pre-incubated in the absence or presence of 10 µM AZ10606120, and 1 mM ATP-induced YO-PRO-1 2+ uptake into B cells determined by flow cytometry. C57BL/6 mice were studied because of the
P2X7 activation induces rapid CD23 shedding from murine B cells
To determine if ATP induces CD23 loss from murine B cells, splenic cells were incubated with 1 mM ATP for up to 30 min and cell-surface CD23 expression assessed by flow cytometry (Figure 3a, b) . ATP induced a rapid loss of cell-surface CD23 from B cells from both C57BL/6 and DBA/1 mice with a t 1/2 of approximately 7 min (Figure 3c ).
To determine if ATP-induced CD23 loss was mediated by P2X7, cells from both mouse strains were incubated for 7 min (the t 1/2 ) in the absence or presence of 1 mM ATP, 0.3 mM BzATP, 1 mM ADP or 1 mM UTP. Similar to above (Figure 3c ), ATP induced a 37 ± 4% and 57 ± 4% loss of cell-surface CD23 in B cells from C57BL/6
and DBA/1 mice, respectively (Figure 3d , e). BzATP induced a 33 ± 8% and 58 ± 5% loss of cell-surface CD23 in B cells from C57BL/6 and DBA/1 mice, respectively, while ADP and UTP had no effect compared to cells incubated without nucleotide in either mouse strain (Figure 3d , e).
To confirm that ATP-induced loss of CD23 was mediated by P2X7, cells were preincubated in the absence or presence of 10 µM AZ10606120, and 1 mM ATP-induced CD23 loss determined by flow cytometry. AZ10606120 impaired ATP-induced CD23
loss by 95 ± 8% and 97 ± 6% in B cells from C57BL/6 and DBA/1 mice respectively (Figure 3f, g ). In the absence of ATP, AZ10606120 did not alter CD23 expression in B cells from either mouse strain (Figure 3f, g ). 
P2X7
Recent evidence indicates that Pfizer P2X7 knockout mice, 23 from which the P2X7 knockout mice in the current study were derived, 24 express three novel C-terminal truncated P2X7 variants termed 13A (~60 kDa), 13B (~60 kDa) and hybrid (~70 kDa) P2X7. 28 Pfizer P2X7 knockout mice were generated by targeting exon 13 of the P2RX7 gene, 23 and PCR with primers to exons 9 and 11 of the P2RX7 gene demonstrates P2X7 expression in various tissues from these mice. 28 shedding from C57BL/6 B cells (Figure 6e ).
Discussion
The current study, shows for the first time that P2X7 activation induces the rapid shedding of CD23 from primary human and murine B cells. This was confirmed by a series of experiments. First, ATP induced the rapid cell-surface loss of CD23
shedding with a t 1/2 of approximately 6 and 7 min from human and murine B cells, respectively. Second, the most potent P2X7 agonist BzATP also induced the rapid cell-surface loss of CD23, whereas the non-agonists ADP and UTP had no effect.
Third, a specific P2X7 antagonist, AZ10606120, 19 almost completely impaired ATPinduced CD23 shedding in both human and murine B cells. Fourth, ATP failed to induce CD23 shedding from B cells from C57BL/6 P2X7 knockout mice. Finally, measurements of soluble CD23 (as well as total CD23 expression for murine B cells)
indicated that cell-surface loss of CD23 was due to shedding from both human and murine B cells.
Using the ADAM10 inhibitor, GI254023X, 35 the current study also shows that P2X7-induced CD23 shedding from human and murine B cells is possibly mediated, at least in part, by ADAM10. This finding is consistent with a role for ADAM10 in P2X7-induced CD23 shedding from human RPMI 8226 myeloma cells. 15 Sluyter, unpublished observations). Thus, the possibility remains that P2X7 activation induces cell-surface CD23 shedding through the co-localisation of ADAM10 and CD23, rather than by directly stimulating ADAM10 activity. Finally, using a candidate approach, our previous studies also failed to identify potential intracellular signalling molecules involved in P2X7-induced CD23 shedding. 20 The current study demonstrates the presence of functional P2X7 on murine B cells from both C57BL/6 and DBA/1 mice. is an early event of P2X7-mediated apoptosis. In the current study, 30 min incubation with ATP caused a small but significant amount of apoptosis, determined by forward scatter (cell shrinkage) and 7AAD uptake (loss of membrane integrity), 48 In conclusion, this study demonstrates human and murine P2X7 activation induces the rapid shedding of CD23 from B cells. Moreover, the study indicates a potential role for ADAM10 in this process.
Methods
Reagents
Ficoll Paque TM PLUS was from GE Healthcare Bio-Sciences (Uppsala, Sweden).
DMEM/F12 medium, YO-PRO-1 iodide, TRIzol reagent, and TaqMan Collection, Manassas, VA) were maintained as described.
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Measurement of nucleotide-induced CD23 shedding by flow cytometry
Nucleotide-induced CD23 shedding from cells was indirectly assessed by flow cytometric measurements of ATP-induced loss of cell-surface CD23 as described. 
Measurement of P2X7 by immunoblotting
Immunoblotting of murine cells was performed as described. 53 Briefly, whole cell lysates were separated under reducing conditions using Any kD Mini-PROTEAN TGX Stain-Free Gels (Bio-Rad, Hercules, CA) and transferred to nitrocellulose membrane (Bio-Rad), and immunoblotting was performed using an anti-P2X7
antibody. To confirm equal protein loading between splenic cell samples within stainfree gels, total protein was assessed using a Bio-Rad Criterion Stain Free Imager (results not shown).
Presentation of data and statistics
Data is presented as mean ± SD from individual people or mice except where stated.
Differences between groups were compared using an unpaired Student's t-test for single comparisons or one-way ANOVA (using Tukey's multiple comparison test) except for human ELISA data, for which a paired Student's t-test was used. Statistical comparisons were performed using Prism 5 (Windows version 5.01; GraphPad Software, San Diego, CA) with P < 0.05 considered significant. individuals, or (b, c, e, f) 3 mice); * P < 0.05 and ** P < 0.01 compared to control, and
